Translational approach for pharmacogenomics and personalized medicine

Yaoxue Xuebao

Volumn 46, Issue 1, 2011, Pages 1-5

  Zhang, Wei ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Personalized medicine; Pharmacogenetics; Pharmacogenomics; Translational research

Indexed keywords

DRUG DEVELOPMENT; MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PROFESSIONAL PRACTICE; REVIEW; TREATMENT OUTCOME;

DRUG DISCOVERY; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79551495455     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future [J]. Genome Med, 2010, 2: 57.
2. Carrasco-Garrido P, de Andrés LA, Barrera VH, et al. Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006) [J]. BMC Health Serv Res, 2010, 10: 287.
3. Clayton TA, Lindon JC, Cloarec O, et al. Pharmacometabonomic phenotyping and personalized drug treatment [J]. Nature, 2006, 440: 1073-1077.
4. Amacher DE. Reactive intermediates and the pathogenesis of adverse drug reactions: the toxicology perspective [J]. Curr Drug Metab, 2006, 7: 219-229.
5. Little S. The impact of FDA guidance on pharmacogenomic data submissions on drug development [J]. IDrugs, 2005, 8: 648-650. (Pubitemid 41093868)
6. Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response [J]. Clin Pharmacol Ther, 2007, 81: 328-345.
7. Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base [J]. Methods Mol Biol, 2005, 311: 179-191.
8. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose [J]. Blood, 2008, 112: 1022-1027.
9. Ndegwa S. Pharmacogenomics and warfarin therapy [J]. Issues Emerg Health Technol, 2007, (104): 1-8.
10. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues [J]. J Thromb Thrombolysis, 2008, 25: 45-51.
11. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy [J]. Ther Drug Monit, 2004, 26: 186-191.
12. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia [J]. JAMA, 2005, 293: 1485-1489.
13. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea [J]. Rheumatology (Oxford), 2004, 43: 156-163.
14. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350: 2129-2139.
15. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib [J]. Clin Cancer Res, 2006, 12: 839-844.
16. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence [J]. J Clin Oncol, 2005, 23: 2513-2520. (Pubitemid 47050841)
17. Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma [J]. Am J Clin Pathol, 2006, 125: 860-865. (Pubitemid 43801536)
18. Yang CW, Hung SI, Juo CG, et al. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced. Stevens-Johnson syndrome [J]. J Allergy Clin Immunol, 2007, 120: 870-877.
19. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions [J]. Pharmacogenet Genomics, 2006, 16: 297-306.
20. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome [J]. Nature, 2004, 428: 486.
21. WarfarinDosing. http://www.WarfarinDosing.org.
22. Klein TE, Altman RB, Eriksson N, et al. International warfarin pharmacogenetics consortium, estimation of the warfarin dose with clinical and pharmacogenetic data [J]. N Engl J Med, 2009, 360: 753-764.
23. Iadutiu GD, Isackson PJ. SLCO1B1 variants and statin-induced myopathy [J]. N Engl J Med, 2009, 360: 304.
24. Table of valid genomic biomarkers in the context of approved drug labels. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ ucm083378.htm.
25. Ikediobi ON, Shin J, Nussbaum RL, et al. Addressing the challenges of the clinical application of pharmacogenetic testing [J]. Clin Pharmacol Ther, 2009, 86: 28-31.
26. Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus [J]. Clin Pharmacol Ther, 2003, 73: 435-455. (Pubitemid 36549828)